rifampin and phenylalanine-arginine-beta-naphthylamide

Acinetobacter baumannii are non-fermentative, Gram-negative bacilli that cause a large number of nosocomial infections worldwide. They are characterized by frequent multiresistance due to multiple mechanisms. As a consequence, infections caused by strains exhibiting resistance to carbapenems and, sometimes, polymyxins, are regularly observed. Sulbactam, colistin and combinations of different antimicrobials have been reported as new therapeutic approaches for infections caused by resistant A baumannii strains. This review focuses on current and potential new drugs, such as rifampin, tigecycline, antimicrobial peptides, efflux pump resistant and inhibitor drugs, and enzyme inhibitors.

Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Clinical Trials as Topic; Dipeptides; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Humans; Minocycline; Molecular Structure; Rifampin; Tigecycline

Gene inactivation and complementation experiments showed that the tripartite AheABC efflux pump of Aeromonas hydrophila extruded at least 13 substrates, including nine antibiotics. The use of phenylalanine-arginine-beta-naphthylamide (PAbetaN) revealed an additional system(s) contributing to intrinsic resistance. This is the first analysis of the role of multidrug efflux systems in Aeromonas spp.

Topics: Aeromonas hydrophila; Anti-Bacterial Agents; Bacterial Proteins; Biological Transport, Active; Dipeptides; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Analysis, DNA; Substrate Specificity